These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 877518)

  • 21. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates.
    Kelly P; Penner JA
    JAMA; 1976 Nov; 236(18):2061-4. PubMed ID: 989788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
    Mahasandana C; Patharathienskul D; Suvatte V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.
    Hilgartner MW; Knatterud GL
    Blood; 1983 Jan; 61(1):36-40. PubMed ID: 6401216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment with prothrombin complex concentrate of postoperative bleeding in a haemophiliac with a factor VIII inhibitor.
    Lowe GD; Harvie A; Forbes CD; Prentice CR
    Br Med J; 1976 Nov; 2(6044):1110-1. PubMed ID: 990791
    [No Abstract]   [Full Text] [Related]  

  • 26. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience.
    Tjønnfjord GE
    Haemophilia; 2004 Sep; 10 Suppl 2():41-5. PubMed ID: 15385045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII.
    Kantrowitz JL; Lee ML; McClure DA; Kingdon HS; Thomas WR
    Clin Ther; 1987; 9(4):405-19. PubMed ID: 3111706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between two concentrates with factor VIII inhibitor bypassing activity.
    Vinazzer H
    Thromb Res; 1982 Apr; 26(1):21-9. PubMed ID: 6980497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitor antibodies to factor VIII and factor IX: management.
    Lusher JM
    Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apheresis.
    Nilsson IM; Freiburghaus C
    Adv Exp Med Biol; 1995; 386():175-84. PubMed ID: 8851026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
    Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
    Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
    [No Abstract]   [Full Text] [Related]  

  • 32. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
    Hrubisková K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(4):672-82. PubMed ID: 6162735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Total dental extraction in a patient with F VIII inhibitor.
    Stenbjerg S; Tauris P; Skottun T; Jørgensen J
    Thromb Res; 1980 Jun; 18(6):889-93. PubMed ID: 6774444
    [No Abstract]   [Full Text] [Related]  

  • 35. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.
    Fukui H; Fujimura Y; Takahashi Y; Mikami S; Yoshioka A
    Thromb Res; 1981 Apr 1-15; 22(1-2):177-84. PubMed ID: 6794176
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX.
    Nilsson IM; Hedner U
    Scand J Haematol; 1976 May; 16(5):369-82. PubMed ID: 951577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conjectures on factor VIII bypassing activity.
    Aronson DL
    Prog Clin Biol Res; 1981; 72():103-21. PubMed ID: 6977778
    [No Abstract]   [Full Text] [Related]  

  • 38. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The problem of factor VIII inhibitors in patients with congenital coagulopathies].
    Klare M
    Z Gesamte Inn Med; 1983 Jan; 38(2):47-50. PubMed ID: 6407220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FEIBA safety profile in multiple modes of clinical and home-therapy application.
    Luu H; Ewenstein B
    Haemophilia; 2004 Sep; 10 Suppl 2():10-6. PubMed ID: 15385041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.